首页> 外国专利> HOMODIMERIC FUSED PROTEIN WITH ACTIVITY OF ANGIOGENESIS INHIBITOR (VARIANTS), DNA MOLECULE ENCODING HOMODIMERIC FUSED PROTEIN, VECTOR FOR EXPRESSION OF HOMODIMERIC FUSED PROTEIN, METHOD FOR TRANSFECTION OF MAMMALIAN CELL AND METHOD FOR PREPARING HOMODIMERIC FUSED PROTEIN

HOMODIMERIC FUSED PROTEIN WITH ACTIVITY OF ANGIOGENESIS INHIBITOR (VARIANTS), DNA MOLECULE ENCODING HOMODIMERIC FUSED PROTEIN, VECTOR FOR EXPRESSION OF HOMODIMERIC FUSED PROTEIN, METHOD FOR TRANSFECTION OF MAMMALIAN CELL AND METHOD FOR PREPARING HOMODIMERIC FUSED PROTEIN

机译:具有血管生成抑制剂(变种)活性的均质融合蛋白,编码均质融合蛋白的DNA分子,均质融合蛋白的表达载体,哺乳动物细胞的翻译方法和均质蛋白的制备方法

摘要

FIELD: biotechnology, molecular biology.;SUBSTANCE: invention can be used for preparing fused proteins as inhibitors of angiogenesis. Fused protein represents a homodimer wherein region Fc in immunoglobulin-gamma is fused with the target protein comprising one or some molecules with activity of angiogenesis inhibitor that originates from angiostatin or endostatin. Variant of homodimeric fused protein involves also the second target protein comprising one or some molecules eliciting activity of angiogenesis inhibitor and taken among angiostatin, endostatin, plasminogen fragment eliciting activity of angiostatin, and collagen XVIII fragment eliciting activity of endostatin. Molecules as components of homodimeric used protein are bound with region Fc in immunoglobulin-gamma and each with other directly or by a polypeptide bridge. Homodimeric fused protein is prepared by transfection of mammalian cell with vector comprising DNA molecule encoding the target protein, culturing mammalian cells for producing fused protein and isolation of fused protein. Invention provides effective production and secretion of agiogenesis inhibitors in different hosts - mammalian cells.;EFFECT: improved preparing method, valuable biological and medicinal properties of protein.;13 cl, 6 dwg, 16 ex
机译:领域:生物技术,分子生物学;物质:本发明可以用于制备融合蛋白作为血管生成的抑制剂。融合蛋白代表同型二聚体,其中免疫球蛋白-γ中的Fc区与靶蛋白融合,所述靶蛋白包含一个或一些具有源自血管抑素或内皮抑素的具有血管生成抑制剂活性的分子。同型二聚体融合蛋白的变体还涉及第二靶蛋白,该第二靶蛋白包含一个或一些引发血管生成抑制剂活性的分子,并选自血管抑素,内皮抑素,血管生成抑制素的纤溶酶原片段引发活性和内皮抑素的胶原蛋白XVIII片段引发活性。作为同二聚体使用的蛋白质的成分的分子与免疫球蛋白-γ中的Fc区结合,并且彼此直接结合或通过多肽桥结合。通过用包含编码靶蛋白的DNA分子的载体转染哺乳动物细胞,培养哺乳动物细胞以产生融合蛋白和分离融合蛋白来制备同源二聚体融合蛋白。本发明提供了在不同宿主-哺乳动物细胞中血管生成抑制剂的有效生产和分泌。效果:改进的制备方法,有价值的蛋白质生物学和医学特性; 13 cl,6 dwg,16 ex

著录项

  • 公开/公告号RU2240328C2

    专利类型

  • 公开/公告日2004-11-20

    原文格式PDF

  • 申请/专利权人

    申请/专利号RU20010105917

  • 申请日1999-08-25

  • 分类号C07K14/515;C07K19/00;C12N9/68;C12N15/62;C12N15/85;C12P21/02;

  • 国家 RU

  • 入库时间 2022-08-21 22:02:17

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号